Drug Profile
GTX 101 - GeneTx Biotherapeutics
Latest Information Update: 20 Jul 2022
Price :
$50
*
At a glance
- Originator Texas A&M AgriLife Research; Texas A&M University
- Developer GeneTx Biotherapeutics
- Class Antisense oligonucleotides; Neuroprotectants
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Angelman syndrome